Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1984 Jun;43(3):407–410. doi: 10.1136/ard.43.3.407

A controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma).

J F Fries, C Wasner, J Brown, P Feigenbaum
PMCID: PMC1001359  PMID: 6378105

Abstract

Antihypertensive treatment may be life saving in scleroderma renal crisis. Patients surviving such crises frequently have had dramatic improvement in the dermal manifestations of their scleroderma. To investigate the potential role of antihypertensive treatment in nonhypertensive patients we randomly assigned 28 patients with systemic sclerosis into drug (14) and placebo (14) groups, using blocked randomisation , and followed them up in a prospective, double-blind clinical trial for 24 months. Overall, both groups improved slightly, with both subjective and objective markers. There were no statistically significant differences and no clinically meaningful trends between the 2 groups, except that the blood pressure was reduced in the group on the active drug.

Full text

PDF
407

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker D. J., Farr M. J. Resolution of cutaneous manifestations of systemic sclerosis after haemodialysis. Br Med J. 1976 Feb 28;1(6008):501–501. doi: 10.1136/bmj.1.6008.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Campbell P. M., LeRoy E. C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975 May;4(4):351–368. doi: 10.1016/0049-0172(75)90017-7. [DOI] [PubMed] [Google Scholar]
  3. Fries J. F. The microvascular pathogenesis of scleroderma: an hypothesis. Ann Intern Med. 1979 Nov;91(5):788–789. doi: 10.7326/0003-4819-91-5-788. [DOI] [PubMed] [Google Scholar]
  4. Gavras H., Gavras I., Cannon P. J., Brunner H. R., Laragh J. H. Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? Arch Intern Med. 1977 Nov;137(11):1554–1558. [PubMed] [Google Scholar]
  5. Gershwin M. E. Slow progress with scleroderma. Ann Intern Med. 1982 Nov;97(5):776–778. doi: 10.7326/0003-4819-97-5-776. [DOI] [PubMed] [Google Scholar]
  6. LeRoy E. C., Fleischmann R. M. The management of renal scleroderma: experience with dialysis, nephrectomy and transplantation. Am J Med. 1978 Jun;64(6):974–978. doi: 10.1016/0002-9343(78)90452-7. [DOI] [PubMed] [Google Scholar]
  7. Lopez-Ovejero J. A., Saal S. D., D'Angelo W. A., Cheigh J. S., Stenzel K. H., Laragh J. H. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med. 1979 Jun 21;300(25):1417–1419. doi: 10.1056/NEJM197906213002505. [DOI] [PubMed] [Google Scholar]
  8. Richardson J. A. Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis Rheum. 1973 Mar-Apr;16(2):265–271. doi: 10.1002/art.1780160220. [DOI] [PubMed] [Google Scholar]
  9. Siegel R. C., Fries J. F. Intra-arterially administered reserpine and saline in scleroderma. Arch Intern Med. 1974 Sep;134(3):515–518. [PubMed] [Google Scholar]
  10. Steen V. D., Medsger T. A., Jr, Rodnan G. P. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med. 1982 Nov;97(5):652–659. doi: 10.7326/0003-4819-97-5-652. [DOI] [PubMed] [Google Scholar]
  11. Wasner C., Cooke C. R., Fries J. F. Successful medical treatment of scleroderma renal crisis. N Engl J Med. 1978 Oct 19;299(16):873–875. doi: 10.1056/NEJM197810192991607. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES